Alert

Compatibility Warning

The main WCB-Alberta website and its online applications use JavaScript technology and some cookies. Please ensure you have JavaScript and cookies enabled in your browser. Visit the help page for more information.

Click here to see an important notice
Workers Compensation Board Alberta Logo

-A A +A

WCB Procedures

  • Help
    • Searching for a procedure or within a procedure
  • 1 - Claim entitlement decisions
    • 1-1 Initial entitlement decision
    • 1-2 Initial entitlement decision - psychiatric or psychological injury
    • 1-3 Initial entitlement decision - hearing loss
    • 1-4 Benefits during a medical investigation
    • 1-5 Claim reopen (continuation or recurrence) decision
    • 1-6 Aggravation of a pre-existing condition decision
    • 1-7 Reconsider a previous decision (new evidence)
    • 1-8 Fitness-for-work decision
    • 1-9 Conflict of medical/psychologist opinion
    • 1-10 Additional entitlement decision
    • 1-16 Medical assistance in dying
  • 2 - Compensation rate setting and disbursements (payments)
    • 2-1 Rate setting
  • 3 - Return-to-work and care planning
    • 3-1 Modified work
    • 3-2 Collaborative care planning
    • 3-3 Duty to cooperate
    • 3-4 Egregious conduct
    • 3-5 Obligation to reinstate employment
    • 3-8 Medical panel
    • 3-9 Employer-requested medical examination
  • 4 - Medical benefits and services
    • 4-1 Medical testing, referrals and program support
    • 4-2 Community treatments
    • 4-3 Psychological counselling
    • 4-4 Orthotics and prosthetics
    • 4-5 Home health care
    • 4-6 Special services and equipment
    • 4-7 Opioid management
    • 4-8 Pharmacy direct billing and medication management
    • 4-9 Pharmaceutical cannabinoids and medical cannabis
    • 4-10 Externally-powered prosthetics
    • 4-11 Non-standard medical aid treatment decision
  • 5 - Claim-related expenses
    • 5-1 Travel and subsistence benefits
    • 5-5 Child and animal care
    • 5-6 Home and workplace modifications
    • 5-7 Vehicle modifications
    • 5-8 Initial hospitalization, treatment center and care facility benefits
    • 5-10 Special financial assistance
    • 5-13 Lump sum retirement (pre-retirement) benefit approval
  • 6- Permanent disability benefits
    • 6-1 Permanent clinical impairment
    • 6-2 Permanent total disability decision
    • 6-3 Advances and lump sum commutation requests
  • 7 - Re-employment benefits and services
    • 7-1 Triage assessment referral
    • 7-2 Supported job search
    • 7-4 Retraining programs
    • 7-5 Training on the job, train and place, or work assessment
    • 7-6 Designated public service employers
    • 7-7 Relocation assistance
    • 7-8 Alternate grants -retraining and self-employment
    • 7-9 Tools and equipment
  • 8 - Wage loss supplements
    • 8-1 Wage loss supplement final approval
    • 8-2 Retroactive wage loss supplement final approval
    • 8-3 Temporary partial disability benefit (TPD) reviews
    • 8-4 Temporary economic loss (TEL) benefit reviews
  • 9 - Claim information, access and privacy
    • 9-4 Authorizations: worker and employer representatives
  • 10 - Client inquiries and incidents
    • 10-1 Client inquiry resolution
    • 10-2 Respectful communication
    • 10-3 Critical incidents
    • 10-4 Address a fairness inquiry
  • 11 - Claim and file administration
    • 11-1 Requesting medical reports
    • 11-2 Internal consultant referrals
    • 11-4 Translation and interpretation services
    • 11-5 Claim entitlement Investigation Unit referrals
    • 11- 8 Guardianship and trusteeship
  • 12 - Cost and entitlement adjustments
    • 12-1 Cost relief, cost transfer and cost reallocation
    • 12-3 Overpayments, cost corrections and payments on hold
  • 13 - Claim decision review and appeal
    • 13-1 Address a resolution submission or letter

Pharmaceutical cannabinoids and medical cannabis

Procedure summary

Published On

Dec 16, 2024
Purpose

To support workers and their treating physicians by providing education and access to pharmaceutical cannabinoids or medical cannabis for a work-related injury or condition.

Description

This process starts when the worker advises that pharmaceutical cannabinoids are being prescribed or medical cannabis is being authorized by their treating physician or the WCB is made aware of its use through other means (for example, physician's reports or prescription receipts). The WCB decision maker works with the worker to gather information to determine whether the request meets all the criteria for approval for pharmaceutical cannabinoids or medical cannabis (as outlined in Policy 04-06, Part II, Application 6- Pharmaceutical Cannabinoids and Cannabis Authorized for Medical Use) coverage.

When medical cannabis is approved, the authorizing physician must submit a report every three months. The claim is monitored (by a case assistant) every three months to ensure the medical reporting supports that the criteria for continued approval for medical cannabis is being met. If not, the claim is sent to a case manager to review and determine if approval for medical cannabis should continue. If the criteria for continued payment for medical cannabis is being met, the claim continues to be monitored until the annual review period, at which point the claim is sent to the decision maker to consider an extension of the approval for medical cannabis, if appropriate for the worker’s needs.

Key information

Policy 04-06, Part II, Application 6- Pharmaceutical Cannabinoids and Cannabis Authorized for Medical Use, outlines information about pharmaceutical cannabinoids and medical cannabis coverage. It is important for staff and viewers to review the specific questions in policy to ensure all information is considered in the decision. 

Pharmaceutical cannabinoids are prescription drugs approved by Health Canada and have a drug identification number (DIN). These include Sativex and Nabilone. They may be prescribed in one of two ways, and have different criteria to monitor:

  • Official indications (Health Canada approved uses i.e., nausea and vomiting associated with cancer therapy or palliative end-of-life care). These should be monitored as per usual prescribed medications.
  • “Off-label” use (for conditions not officially approved by Health Canada). There are only specific diagnoses that would be considered for coverage (Question 6 in policy). They can be covered if as a trial for treatment before medical cannabis can be covered. These are not medical cannabis, so these do not have the additional requirements (Questions 8-12 in policy) such as, a treatment agreement or a report from the prescribing physician every three months. But, as these are prescribed “off label”, regular physician reporting as to efficacy and side-effects should be monitored. 

The Federal Cannabis Regulations allow some health care professionals to authorize (not prescribe) medical cannabis.  Some health care professionals are allowed to authorize (not prescribe) medical cannabis under certain conditions (Questions 2-5 in policy) however, it is not a prescription drug approved by Health Canada. It also does not have a DIN number or natural product number (NPN). Medical cannabis authorized for medical use includes commercially prepared dried cannabis, topical preparations, oils and edibles from Health Canada suppliers licensed to sell to a registered patient for medical purposes.  Medical cannabis authorized for medical use does not include fresh plants or seeds. A treatment agreement is required for WCB to approve payment for medical cannabis. 

Generally, pharmaceutical cannabinoids and medical cannabis are not prescribed or authorized when a worker is in the acute stage of recovery from their injury (immediately following an accident) or after surgery. It is not intended to be a first-line solution for pain management due to limited evidence for this purpose, and because it can cause significant harm.

To approve pharmaceutical cannabinoids or medical cannabis, a worker must have a designated condition and meet all the criteria for approval of either pharmaceutical cannabinoids or medical cannabis (Questions 6, 7, 8 and 11 in the policy). The worker must also complete their responsibilities (Question 11 in the policy).  

WCB only approves doses and administration routes that align with Health Canada’s Information for Health Care Professionals and relevant Standard(s) of Care and Advice to the Profession developed by the CPSA (Question 12 in the policy). 

After approval of medical cannabis, a clinical reassessment by the worker's authorizingThe authorizing physician must be the treating physician for the worker's compensable injury. physician is required every three months. Coverage will continue if there is sufficient evidence the medical cannabis is effective, measurable treatment goals are reached and maintained and there are no adverse effects that outweigh the benefits. 

Coverage for medical cannabis may be suspended or ended when it is no longer necessary and/or appropriate, it impedes return to work, or there is evidence of misuse (Question 14 in the policy).  

Detailed business procedure

Expand all

Collapse all

1. Determine if the worker has a designated condition to consider approval for pharmaceutical cannabinoids or medical cannabis

Review the request for pharmaceutical cannabinoids for approval (from the worker or physician via reporting). For pharmaceutical cannabinoids or medical cannabis determine if the worker has any of the designated conditions for which pharmaceutical cannabinoids or medical cannabis may be considered, as outlined in Policy 04-06, Part II, Application 6 - Pharmaceutical Cannabinoids and Cannabis Authorized for Medical Use, Question 6. If there is a Health Canada approved usage, monitor as usual for medication use.

If unsure whether a worker has one of the designated conditions, request a medical consultant opinion. Once the opinion is received determine if the worker has one of the designated conditions. 

If the worker does not have one of the designated conditions, contact them to explain the decision not to approve coverage. Communicate the decision in writing.

Administrative tasks

Document the conversation in a file note (Medication & Dressings/Details). 

 

Follow procedure 11-2 Internal consultant referrals.

Send the Medical Cannabis - Denial (CL036B) letter. 

Attach all file notes and letters to the Authorized Medication (AUM) line.

2. Contact the worker to discuss next steps

Discuss the following details with the worker:

Pharmaceutical cannabinoids
  • The worker must have a designated condition (Question 6 in policy) and meets the criteria for approval (Question 7 in policy). If the worker is being prescribed pharmaceutical cannabinoids for off-label use, discuss the additional criteria for off-label use (Question 7 of policy). 
  • The dosage and administration routes must align with Health Canada's Information for the Health Care Professions and relevant Standard(s) of Care and Advise to the Professions developed by CPSA (Question 12 in policy). 
Medical cannabis only 
  • The worker must have a designated condition (Question 6 of the policy) and meet the criteria for approval (Question 8 of the policy). 
  • If the worker has not completed an appropriate trial (3 months) of pharmaceutical cannabinoids that was unsuccessful (unless pharmaceutical cannabinoids are contraindicated), advise the worker that a trial must be completed before approval for medical cannabis can be considered. 
  • If pharmaceutical cannabinoids are contraindicated, advise the worker that a medical consultant must review the claim before approval for medical cannabis can be considered to ensure the same contraindications for pharmaceutical cannabinoids do not prevent the worker from safely using medical cannabis.
  • The worker’s responsibilities that must be met to approve medical cannabis (Question 11 in policy).
  • The WCB approved dosage and administration route for dried cannabis (Question 12 in policy).  
  • An information package will be issued which includes the documents required for approval, including forms that must be completed with the physician that is authorizing medical cannabis.
  • When the worker expects to see their physician to have the forms completed.
  • Coverage starts when all the required forms in the information package are signed by the worker and their physician and received on file.
  • Continued approval will be reviewed every three months and the criteria that must be met to continue approval (Question 13 in policy).
  • When the WCB is considering suspending or ending coverage (Question 14 in policy).

When reviewing for approval for medical cannabis only, send the appropriate letter documenting the discussion and plan to determine entitlement and attach the appropriate forms to be completed by the worker and the authorizing physician. A letter is not required when reviewing for approval for pharmaceutical cannabinoids.

If the worker could not complete a trial of pharmaceutical cannabinoids because they are contraindicated, request a medical consultant review to ensure medical cannabis is not also contraindicated.

Administrative tasks

Document the discussion in a file note (Medication & Dressings/Details).  

For medical cannabis only:

  • Send the Medical Cannabis Worker (CL036D) Letter with Package.
  • Attach the appropriate forms to be completed by the worker and physician. 

Follow the instructions in the Email or print and mail letter and forms section, as required. 

Forms to be attached:

  • Worker Fact Sheet – Medical Cannabis
  • Physician's Guide to authorizing cannabinoids for medical use
  • Medical Cannabis Treatment Agreement (FM036A)
  • Opioid Risk Assessment Checklist (C942)
  • Medical Cannabis Management Report (C1446)
  • Cannabis-Medical-Patient-Booklet (Cannabis – Questions about cannabis and the answers that may surprise you) 

 

 

 

 

 

Follow the 11-2 Internal consultant referrals procedure.

3. Make the decision

Pharmaceutical cannabinoids

When reviewing for approval of pharmaceutical cannabinoids, determine if the request meets the criteria identified in policy (Policy 04-06, Part II-Application 6).  

If the request does not meet the criteria, call the worker to explain why and send the appropriate letter.  Do not continue with this procedure.

Medical cannabis

When reviewing for approval of medical cannabis, review the forms to ensure they are completed and signed by the worker and physician. If all required forms are not received or information is missing, contact the worker to request the information. Send the appropriate letter and monitor for the missing information.

Note: The authorizing physician is the treating physician who is responsible for the ongoing care of the worker's compensable medical condition or symptoms for which the medical cannabis is authorized.

Determine if the request meets the criteria identified in policy including dosages, THC content, administration route, etc. (Questions 7, 8 and 12 in policy). 

If the worker is taking a higher dose than what is allowed in policy, WCB will pay up to the amount that policy allows and the worker is responsible for paying the remainder

If the request does not meet the criteria, contact the worker to explain why and send the appropriate letter. Do not continue with this procedure.

Administrative tasks

Update the Authorized medication (AUM) line with the decision. Follow the instructions provided in the Updating the Authorized medication line for the approval section. 

Document the discussion in a file note (Medication & Dressings/Details).

Send the appropriate letter:

  • Medical Cannabis - Denial (CL036B)
  • Medical Cannabis - Missing Information (CL036C)  

 

 

 

In cases where the worker is taking a higher dose than is allowed in policy the claim owner will: 

  • Add a file note (Medication & Dressings/Details).
  • Include how much of the prescribed dose is payable by WCB and how much should be covered by the worker.
  • Attach to the authorized medication (AUM) line.

Example: If the worker is prescribed 5g of medical cannabis per day and the maximum allowable in policy is 3g per day then WCB will issue a payment for 3g per day and the worker will be responsible for paying the additional 2g per day.

4. Communicate the approval decision to the worker

Contact the worker and explain that pharmaceutical cannabinoids or medical cannabis is approved.

Pharmaceutical cannabinoids

Confirm that the medication will be approved for one year, at which time an annual review will be completed. Communicate the decision and discussion in writing.

Transfer the claim to the case assistant, when appropriate, to monitor until the next annual review. Do not continue with this procedure.

Medical cannabis

Discuss (and document) the following:

  • Approval is for the initial three months. 
  • After three months, a review will be completed to determine if coverage can continue.  This will be repeated every three months.  After one year, an annual review will also be completed.
  • The worker’s physician must submit reporting every three months demonstrating functional improvement with medical cannabis. Coverage will continue if there is sufficient evidence the medical cannabis is effective, measurable treatment goals are reached and/or maintained and there are no adverse effects that outweigh the benefits.  
  • Costs will include the purchase of a vaporizer if dried cannabis is being authorized. 
  • Itemized receipts are required, including the amount of product purchased, the THC content or percentage of the cannabis. If the cannabis is in a form other than dried product (such as oil or edibles), the receipt must include the equivalency factor of dried cannabis for calculation purposes.

Communicate the decision and discussion in writing.

Transfer the claim to the case assistant, when appropriate to monitor and review the claim every three months.

Administrative tasks

Document the discussion in a file note (Medical Payment Processing) including the items identified to confirm with the worker.  

Update the Authorized Medications line screens with the approval. Follow the instructions provided in the Updating the Authorized medication line for the approval section. 

Send the appropriate letter:

  • Pharmaceutical Cannabinoid Approval (CL036A) 
  • Medical Cannabis Approval (CL036F) (The letter will include a Cannabis Retailer and Producer fact sheet outlining the information required in the receipts.)

To transfer the claim, send a file note (Medical Payment Processing) to the case assistant and include the required information. Follow the instructions provided in the Transfer file note template content section. 

5. Monitor the claim and conduct quarterly reviews

Review the transfer file note and add a task to review the claim in three months from the approval date.

On the review date, confirm that:

  • A clinical reassessment was completed, and the Medical Cannabis Management Report (C1446) was submitted by the physician. Request reporting from the physician if it is not available on the claim for the review; monitor for its submission. 
  • The medical reporting is consistent, and the dosage, administration routes and prescribing/authorizing physician remains the same. (Question 12 in policy)
  • The plan is effective, showing evidence of improvement in pain levels, improvement in functional scoring and the pain and functional scores correlate with opinion of other physicians involved in the worker's care (e.g., functional capacity evaluation (FCE) reports, other medical reports on file and the decision maker's impression from discussion with the worker.)  The treating physician's Medical Cannabis Management Report (C-1446) must demonstrate this information every three months (Question 13 in policy). 
  • Measurable treatment goals are reached and maintained (Question 13 in policy).
  • There are no adverse effects that outweigh the benefits (Question 13 in policy).
  • If being used to decrease opioid use, there is a decrease in opioid use and not an increase. The decrease in opioid use should be 30% or showing progression towards that (Question 13 in policy).
  • There is no evidence that the use of medical cannabis is impeding return to work or of misuse and the physician continues to indicate it is necessary/appropriate. (Question 14 in policy).

If the worker continues to meet the criteria to receive medical cannabis, document the outcome of the review in eCO. Repeat this step until the approval end date.

If it appears that the worker no longer meets the criteria to approve medical cannabis, transfer the claim to the decision maker. 

If the report is not received, follow the 11-1 Requesting medical reports procedure.

Annual review

Four weeks prior to the annual review date, review the claim to confirm a recent Medical Cannabis Management Report (C1446) is on file from the physician. If the report is not on file, send a request to the physician for the report. Follow the 11-1 Requesting medical reports procedure.

Transfer the claim to a decision maker two weeks prior to the approval end date.  

Administrative tasks

Send the Request Medical Cannabis Management Report (SP036A) letter to request the Medical Cannabis Management Report (C1446), if needed. 

 

Document the outcome of the review in a file note (Medical Payment Processing).

 

Add a task to review the claim in three months (if the next review will be the final review prior to the approval end date, set the task for three months less four weeks).

6. Complete a review and determine if the authorization will be extended

Confirm that:

  • Clinical reassessments are being completed and the Medical Cannabis Management Report (C-1446) is being submitted by the physician every three months.
  • The medical reporting is consistent, and the dosage and physician remains the same (Question 12 in policy).
  • The plan is effective, showing evidence of improvement in pain levels.
  • Measurable treatment goals are reached and maintained.
  • There are no adverse effects that outweigh the benefits.
  • If being used to decrease opioid use, there is a decrease in opioid use (by 30% or showing progression towards that) and not an increase.
  • There is no evidence that the use of medical cannabis is impeding return to work or of misuse and the physician continues to indicate it is necessary/appropriate. 

If unsure whether a worker continues to meet the criteria, request a medical consultant opinion. Once the opinion is received determine if the worker continues to meet the criteria.

Contact the worker to discuss the decision. If the worker meets the criteria for extension, explain that authorization will be provided for another year with reviews every three months to ensure the worker continues to meet the criteria for approval. 

If the worker does not meet the criteria for extension, explain why they no longer meet all of the criteria. Document the discussion and communicate the decision in writing.

When an extension is approved, transfer the claim to the case assistant to monitor and review the claim every three months, when appropriate. Repeat steps 5 and 6 until authorization ends.

Administrative tasks

Document the discussion in a file note (Medical Payment Processing).

Update the Authorized medication (AUM) line with the decision.

 

Follow the 11-2 Internal consultant referrals procedure.

Send the appropriate letter based on the decision:

  • Medical Cannabis Approval (CL036F) letter.
  • Medical Cannabis - Denial (CL036B) letter

To transfer the claim, send a file note (Medical Payment Processing) to the case assistant and include the required information. Follow the instructions provided in the Transfer file note template content section. 

Supporting information

Expand all

Collapse all

Pharmaceutical cannabinoids or medical cannabis authorized before September 1, 2022

When pharmaceutical cannabinoids or medical cannabis were authorized prior to September 1, 2022, renewals on these claims will be adjudicated according to Policy 04-06, Part II, Application 6, Question 16 (the Policy applies to new entitlement decisions and extensions).

Adjudication at renewal of pharmaceutical cannabinoids or medical cannabis applies to all claims including:

  • Appeals Commission decisions directing coverage for a condition that is not a designated condition or for coverage of medical cannabis above the approved dosage in Policy.  (Question 12 in policy)
  • Claims where the dosage or THC content exceeds the limit in Policy. (Question 12 in policy) 
  • Claims where the worker does not have a designated condition.
  • Claims where coverage was applied using the non-standard treatment policyPolicy 04-06, Part II, Application 1 - , such as Post Traumatic Stress Disorder (PTSD). The non-standard treatment policy would no longer apply and the new policy would be used to make the decision.

See Policy 04-06, Part II, Application 6- Question 12.

Updating the eCO Authorized Medication (AUM) line for the approval

Pharmaceutical cannabinoids:
  • Drug Search: Select DIN or drug name and enter the type of pharmaceutical cannabinoid that is being approved per the reference table below.
Active ingredient (s)Trade nameDrug information number (DIN)
Cannabidiol and THCSativex02266121
NabiloneCesamet00548375
02256193
02312263
ACT nabilone02393581
02393603
APO-nabilone02441497
02441500
02441519
PMS-nabilone02380897
02380900
02380919
Teva-nabilone02384884
02384892
02392925
  • Benefit Details: Enter the start and end dates (that is, one year from the start date, for example, September 1 to August 31), the physician’s name, the maximum limitation field with the composition of the medication, the strength and the prescribed dosage (for example, Tablet, 10 mg., 3 per day). Enter the benefit decision and select Add.
  • Additional Details: Enter any additional details required.
Medical cannabis:
  • Drug Search: select DIN, enter the DIN code 99999909 and select Search. (This will populate the benefit details (Cannabis <=9%) authorizing cannabis up to 9% THC.)
  • Benefit Details: Enter the start and end dates (that is, one year from the start date, for example, September 1 to August 31), the physician’s name, the benefit decision and select Add.
  • Additional Details: Enter the details of the type of cannabis authorized, the THC level and the daily amount, (for example, dried cannabis, edibles or oil), and whether a vaporizer is authorized.
Transfer file note template content

Complete the file note template (include details appropriate for the claim circumstances):

Pharmaceutical cannabinoids

I have authorized pharmaceutical cannabinoids for the worker. 

  • Medication name:
  • Authorization period:
  • Dosage:
  • Prescribing physician:
Medical cannabis

I have authorized medical cannabis for the worker. 

  • Type of cannabis authorized:
  • Authorization period:
  • Grams per day:
  • Authorizing physician:

Please review every three months, as per Policy 04-06, Part II, Application 6 to monitor that:

  • A clinical reassessment is completed, and the Medical Cannabis Management Report (C1446) is submitted by the physician. 
  • The medical reporting is consistent, and the dosage and physician remains the same.
  • The plan is effective, showing evidence of improvement in pain levels.
  • Measurable treatment goals are reached and maintained.
  • There are no adverse effects that outweigh the benefits.
  • If being used to decrease opioid use, there is a decrease in opioid use (by 30% or showing progression towards that) and not an increase.
  • There is no evidence that the use of medical cannabis is impeding return to work or of misuse and the physician continues to indicate it is necessary/appropriate. 

If the criteria for continued coverage are not being met, please transfer the claim back for review.

Note: If the report is not received as required, request the report from the physician and monitor for it to be received. 

Email or print and mail the CL036D letter and forms

To email the letter and forms:
  • Create the Medical Cannabis Worker Letter with Package (CL036D).
  • Select Electronic Delivery in the Delivery screen and enter the worker's email (if not already displayed).
  • Click on Add Template Attachments in the Document Attachments screen.
  • Search for and select the Medical Cannabis Package and click Attach. (The attachment documents will display in orange text at the top of the Delivery screen.)
  • Complete the letter.
To print the letter and forms for mailing:
  • Go to the internal Electronic Workplace (EW), Business Tools and select Letter Pull Request.
  • Select New Pull Request (on the left).
  • Complete the Letter Information section.
  • In the Additional Comments section under Other Comments, list the required forms to attach to the letter (see the forms listed below). 
  • In the Attachments section, attach the PDF of the CL036D letter and the Cannabis-Medical-Patient-Booklet PDF.
  • Submit the form.

Forms and other resources:

  • Worker Fact Sheet – Medical Cannabis
  • Physician's Guide to authorizing cannabinoids for medical use 
  • Medical Cannabis Treatment Agreement (FM036A)
  • Opioid Risk Assessment Checklist (C942)
  • Medical Cannabis Management Report (C1446)
  • Cannabis-Medical-Patient-Booklet (Cannabis – Questions about cannabis and the answers that may surprise you) 

Supporting references

Policies

  • Policy 04-06, Part I - Health Care
  • Policy 04-06, Part II, Application 1 - General
  • Policy 04-06, Part II, Application 6 - Pharmaceutical Cannabinoids and Cannabis Authorized for Medical Use

Procedures

  • 11-2 Internal consultant referrals
  • 11-1 Requesting medical reports

Related links

  • Health Care Provider Fact Sheet
  • Worker Fact Sheet
  • Employer Fact Sheet
  • Physicians guide to authorizing cannabinoids for medical purposes
  • Cannabis Retailer and Procedure Fact Sheet

Workers’ Compensation Act

Applicable sections

  • Section 19

General Regulation

Applicable sections

Related Legislation

Applicable sections


Procedure history

February 27, 2024 - December 15, 2024
WCB logo image

Contact WCB-Alberta

Edmonton: 780-498-3999
Calgary: 403-517-6000

Toll free

Alberta: 1-866-922-9221
Canada wide: 1-800-661-9608

Copyright ©2023 The Workers' Compensation Board – Alberta. All rights reserved.